Physician profile
David Petros
NPI 1154306603
$16,772.79
in general payments reported to CMS, 2019-2025
39 companies · $1,243 in 2025
The $1,243 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,371 · 2020: $630 · 2021: $1,015 · 2022: $1,990 · 2023: $4,061 · 2024: $2,461 · 2025: $1,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,576 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,575.84 |
| Education | $189.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,735.53 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,238.67 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $1,319.44 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $1,283.15 | 2022-2024 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $1,110.98 | 2021-2025 | Saphnelo |
| Pfizer INC. | $885.50 | 2019-2024 | |
| Glaxosmithkline, LLC. | $717.14 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $594.82 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $565.19 | 2019-2024 | Orencia |
| Ucb, INC. | $442.22 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $412.65 | 2021-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $344.36 | 2022-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $270.27 | 2019-2021 | |
| Lilly USA, LLC | $258.47 | 2021-2024 | Taltz, Olumiant |
| Organon LLC | $244.96 | 2023-2024 | Renflexis, Hadlima |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $170.44 | 2023-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.17 | 2023-2024 | Cyltezo, Ofev |
| Mallinckrodt Enterprises LLC | $134.81 | 2019 | |
| Fresenius Kabi USA, LLC | $118.51 | 2023-2024 | Idacio |
| Genzyme Corporation | $96.92 | 2020 | |
| Janssen Scientific Affairs, LLC | $85.88 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $69.07 | 2023-2024 | Truxima |
| Genentech USA, INC. | $66.57 | 2019-2025 | Actemra |
| Sanofi-Aventis U.S. LLC | $64.99 | 2023 | |
| Sandoz INC. | $51.11 | 2020-2023 | Hyrimoz |
| Janssen Pharmaceuticals, INC | $48.54 | 2019 | |
| Idorsia Pharmaceuticals US INC | $47.95 | 2023 | Quviviq |
| Genentech, INC. | $44.56 | 2023 | Gazyva |
| Sobi, INC | $40.84 | 2023-2024 | |
| Octapharma USA, INC. | $40.00 | 2024 | Octagam Immune Globulin (Human) |
| Horizon Therapeutics Plc | $39.24 | 2021 | |
| Grifols USA, LLC | $35.95 | 2022-2023 | Gamunex-C |
| Kowa Pharmaceuticals America, INC. | $17.31 | 2023 | Seglentis |
| Celltrion USA INC. | $16.14 | 2023 | Yuflyma |
| Ultragenyx Pharmaceutical INC. | $12.44 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Petros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.